RecruitingNCT00359684

Use of Cysteamine in the Treatment of Cystinosis


Sponsor

National Human Genome Research Institute (NHGRI)

Enrollment

330 participants

Start Date

Jan 4, 1979

Study Type

OBSERVATIONAL

Conditions

Summary

Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle. The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues. This study has several goals: 1. Long-term surveillance of cysteamine treated patients. 2. Detection of new non-kidney complications of cystinosis. 3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\<TAB\>


Eligibility

Min Age: 1 WeekMax Age: 115 Years

Plain Language Summary

Simplified for easier understanding

This study investigates the use of cysteamine (a medication that reduces cystine buildup) in treating cystinosis, a rare inherited metabolic disorder where the amino acid cystine accumulates in cells and damages organs, particularly the kidneys and eyes. You may be eligible if: - You have a confirmed diagnosis of cystinosis (classical or variant forms), demonstrated by elevated leucocyte cystine levels - You are at least 1 week old - You are able to travel to the NIH for evaluation You may NOT be eligible if: - You are unable to travel to the NIH - You are less than one week old - You are a nonviable newborn or a newborn of uncertain viability Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCysteamine

Cystine-depleting agent


Locations(1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00359684


Related Trials